Piper Sandler analyst Jason Bednar lowered the firm’s price target on Merit Medical (MMSI) to $105 from $110 and keeps an Overweight rating on the shares. The firm notes the company announced Q2 revenue consistent with the pre-release of $382.5M/+12.5% cc, and EPS of $1.01 finished ahead of Street’s 85c with margin upside materializing once again. Guidance was raised for operational and tariff factors, and it’s this upper end that seems likely to be in play assuming no major new surprises on the tariff front, Piper adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical Systems: Strong Q2 Performance and Strategic Initiatives Justify Buy Rating
- Merit Medical Board Members’ Trading Plans: A Signal of Insider Intentions and Market Impact?
- Merit Medical Sees Strong Q2 Revenue Growth
- Merit Medical Systems Reports Strong Q2 2025 Results
- Merit Medical reports Q2 adjusted EPS $1.01, consensus 85c